Jon Hamilton

Jon Hamilton is a correspondent for NPR's Science Desk. Currently he focuses on neuroscience and health risks.

In 2014, Hamilton went to Liberia as part of the NPR team that covered Ebola. The team received a Peabody Award for its coverage.

Following the 2011 earthquake and tsunami in Japan, Hamilton was part of NPR's team of science reporters and editors who went to Japan to cover the crisis at the Fukushima Dai-ichi nuclear power plant.

Hamilton contributed several pieces to the Science Desk series "The Human Edge," which looked at what makes people the most versatile and powerful species on Earth. His reporting explained how humans use stories, how the highly evolved human brain is made from primitive parts, and what autism reveals about humans' social brains.

In 2009, Hamilton received the Michael E. DeBakey Journalism Award for his piece on the neuroscience behind treating autism.

Before joining NPR in 1998, Hamilton was a media fellow with the Henry J. Kaiser Family Foundation studying health policy issues. He reported on states that have improved their Medicaid programs for the poor by enrolling beneficiaries in private HMOs.

From 1995-1997, Hamilton wrote on health and medical topics as a freelance writer, after having been a medical reporter for both The Commercial Appeal and Physician's Weekly.

Hamilton graduated with honors from Oberlin College in Ohio with a Bachelor of Arts in English. As a student, he was the editor of the Oberlin Review student newspaper. He earned his master's degree in journalism from Columbia University, where he graduated with honors. During his time at Columbia, Hamilton was awarded the Baker Prize for magazine writing and earned a Sherwood traveling fellowship.

Nearly 200 miles from the nearest ocean, nine surfers are bobbing beneath the Texas sun in what looks like a tropical lagoon.

Then a sound like a muffled jet engine fills the air, overwhelming a reggae song coming from shore.

One surfer starts to paddle, and a head-high wave rises seemingly from nowhere to carry him down the line toward the sandy beach.

Nearly two months after the Alzheimer's drug Aduhelm received conditional approval from the Food and Drug Administration, experts are still debating how, and whether, it should be used.

Before she got COVID-19, Cassandra Hernandez, 38, was in great shape — both physically and mentally.

"I'm a nurse," she says. "I work with surgeons and my memory was sharp."

Then, in June 2020, COVID-19 struck Hernandez and several others in her unit at a large hospital in San Antonio.

"I went home after working a 12-hour shift and sat down to eat a pint of ice cream with my husband and I couldn't taste it," she says.

The loss of taste and smell can be an early sign that COVID-19 is affecting a brain area that helps us sense odors.

Soon after Phillip Lynn got married in 2014, he began to forget things. He'd repeat himself. He'd get lost in places close to the couple's home in a suburb of St. Louis.

Then in 2016, his spouse, Kurt Rehwinkel, realized that Lynn's memory problems had become more severe.

They'd just visited some friends who'd gone to Hawaii with them three months earlier. When they'd talked about the trip, Lynn had become confused.

People recovering from a stroke will soon have access to a device that can help restore a disabled hand.

The Food And Drug Administration has authorized a device called IpsiHand, which uses signals from the uninjured side of a patient's brain to help rewire circuits controlling the hand, wrist and arm.

Pages